IGF1 and pancreatic neoplasm: In pancreatic cancer, IGF-I induces K394 deacetylation via the PI3K/AKT/mTOR signaling pathway and stimulates enolase 2 (ENO2) activity by increasing the phosphorylation of histone deacetylase 3 (HDAC3) of S424, a key glycolytic enzyme in glycolysis metabolism, thus promoting liver metastasis of pancreatic ductal adenocarcinoma (PDAC) (138).